论文部分内容阅读
目的通过检测柔红霉素(DNR)化疗后患者血浆N末端脑利钠肽原(NT-pro BNP)水平以评价DNR早期心肌毒性及参麦注射液对心脏的保护作用。方法将83例急性髓细胞白血病患者随机分为对照组和治疗组,均采用柔红霉素联合阿糖胞苷(DA)方案诱导化疗;治疗组另给予参麦注射液静脉滴注。观察治疗前后患者血浆NT-pro BNP水平、心肌酶谱(CK、CK-MB)和心电图(ECG)变化。结果治疗组中医证候疗效优于对照组(P<0.05)。治疗后,两组NT-pro BNP水平均显著上升(P<0.01),且两组之间有显著差异(P<0.05);两组治疗前后心肌酶含量变化不明显(P>0.05)。结论参麦注射液可降低柔红霉素化疗后患者血浆NT-proBNP水平以防治其心肌毒性。
Objective To evaluate the early myocardial toxicity of DNR and the protective effect of Shenmai injection on the heart of DN patients by detecting the plasma N-terminal pro-brain natriuretic peptide (NT-pro BNP) levels in patients with daunorubicin (DNR) chemotherapy. Methods 83 cases of acute myeloid leukemia were randomly divided into control group and treatment group. Both of them were induced by daunorubicin combined with cytarabine (DA). In the treatment group, Shenmai injection was given intravenously. The plasma levels of NT-pro BNP, myocardial enzymes (CK, CK-MB) and electrocardiogram (ECG) were observed before and after treatment. Results The efficacy of TCM syndromes in treatment group was better than that in control group (P <0.05). After treatment, the levels of NT-pro BNP in both groups increased significantly (P <0.01), and there was a significant difference between the two groups (P <0.05). The levels of myocardial enzymes before and after treatment did not change significantly (P> 0.05). Conclusion Shenmai injection can reduce the level of plasma NT-proBNP in patients with daunorubicin chemotherapy to prevent its myocardial toxicity.